Clinical Trials Logo

Coronary Artery Disease clinical trials

View clinical trials related to Coronary Artery Disease.

Filter by:
  • Not yet recruiting  
  • Page 1 ·  Next »

NCT ID: NCT03523286 Not yet recruiting - Clinical trials for Ischemic Heart Disease

Real-time Automated Program for IDentification of VT Origin

RAPIDVTPilot
Start date: June 2018
Phase: N/A
Study type: Interventional

RAPID-VT Pilot is a single centre prospective cohort pilot study to assess the feasibility, safety and efficacy of catheter ablation of ventricular tachycardia (VT) guided by a novel real-time software to localize the origin of VT during the ablation procedure.

NCT ID: NCT03523026 Not yet recruiting - Clinical trials for Coronary Artery Disease

The Effects of Muscle Training in Coronary Artery Patients With Metabolic Syndrome

Start date: May 10, 2018
Phase: N/A
Study type: Interventional

The aim of this study is to investigate the effects of peripheral and respiratory muscle training on respiratory muscle strength, respiratory functions, exercise capacity and quality of life in coronary artery patients with metabolic syndrome. Prospectively, randomly, double-blind, and controlled study. Stable coronary artery patients with metabolic syndrome will be included to the study from the Istanbul University Cardiology Institute clinic. Patients will be randomized into 3 groups; Neuromuscular Electrical Stimulation (NMES) and Peripheral Muscle Training Group (n: 20): 3 days per week for 6 weeks duration. Peripheral Muscle Training will be applied by elastic band and Proprioceptive Neuromuscular Facilitation three times per week for 6 weeks.Inspirator Muscle Training (IMT) and peripheral muscle training Group (n: 20): IMT will be applied 7 days per week, twice a day for 15 minutes. The program will continue for 6 weeks duration under weekly control of the investigator. Training intensity will set at 30% of the maximum inspiratory pressure.Peripheral Muscle Training will be applied by elastic band and Proprioceptive Neuromuscular Facilitation three times per week for 6 weeks. Peripheral Muscle Training Group (n: 20): Exercise will be applied by elastic band and Proprioceptive Neuromuscular Facilitation three times per week for 6 weeks.Parameters will be recorded before and after training. Evaluation parameters:Demographic and anthropometric measurements, respiratory function test,respiratory muscle strength,dyspnea, peripheral muscle strength, 6 minutes walking test, physical activity, quality of life, depression, sleep quality and laboratory evaluation.

NCT ID: NCT03504982 Not yet recruiting - Clinical trials for Coronary Artery Disease

Study to Evaluate the QT / QTc Interval Prolongation Potential of Vericiguat

Start date: May 30, 2018
Phase: Phase 1
Study type: Interventional

The objective of this study is to evaluate the effect of multiple doses of vericiguat on the QTc interval in patients with stable CAD (coronary artery disease).

NCT ID: NCT03504956 Not yet recruiting - Clinical trials for Coronary Atherosclerosis

Coronary Atherosclerosis T1-Weighted Characterization (CATCH)

CATCH
Start date: May 30, 2018
Phase: N/A
Study type: Interventional

This study proposes to develop an MRI technique named Coronary Atherosclerosis T1-weighed Characterization (CATCH) that will improve the quality and reliability of coronary atherosclerosis evaluation, as well as simplify the scanning process and significantly shorten imaging time compared with conventional imaging methods.

NCT ID: NCT03504202 Not yet recruiting - Clinical trials for Patients With INOCA(Ischemia and no Obstructive Coronary Artery Disease) Who Have Coronary Microvascular Dysfunction

Effect of Trimetazidine on the Improvement of Coronary Microvascular Dysfunction in Patients With INOCA(Ischemia and no Obstructive Coronary Artery Disease)

T-MICRO
Start date: June 1, 2018
Phase: N/A
Study type: Interventional

This is a prospective study which aims to explore the effect of Trimetazidine on the improvement of coronary microvascular dysfunction in patients with INOCA (ischemia and no obstructive coronary artery disease). Enrolled patients will be assessed SAQ(Seattle Angina Score), Canadian Angina Grade(Canadian Cardiovascular Society, CCS), Six-Minute Walk Test, CFR(coronary flow reserve) .CFR inspection with D-SPECT and pressure guide wire.Patients will receive six months Trimetazidine(20mg tid) after enrollment. And their SAQ (Seattle Angina Score), Canadian Angina Grade(Canadian Cardiovascular Society, CCS), Six-Minute Walk Test, CFR will be followed up.

NCT ID: NCT03497637 Not yet recruiting - Clinical trials for Coronary Artery Disease

Comparison of Pd/Pa Versus FFR in Intermediate Coronary Stenoses

LIPSIASTRATEGY
Start date: June 1, 2018
Phase: N/A
Study type: Interventional

This is a prospective, randomized, controlled, multicenter, open-label study designed to assess whether Pd/Pa is non-inferior to FFR when used to guide treatment of intermediate coronary artery stenosis

NCT ID: NCT03491423 Not yet recruiting - Clinical trials for Coronary Artery Disease Without Heart Failure

Short and Fast Step Test: Feasibility, Validity and Tolerance of a Functional Evaluation Test of Lactic Anaerobic Capacities in Patients With Coronary Artery Disease

CORANAE
Start date: April 2018
Phase: N/A
Study type: Interventional

Recommendations for cardiovascular rehabilitation (CVR) encourage exercise training, primarily involving the aerobic system, to allow patients to regain independence in daily activities. However, the lactic anaerobic process is also involved during these activities (stair climbing, carrying loads, etc.). Hence there is a major interest in accurately assessing patients' anaerobic capacities in order to tailor suitable exercise programs. However, there are no functional tests specifically dedicated to the evaluation of lactic anaerobic metabolism and adapted to people with coronary disease. The investigators offer a dedicated test, the short and fast test (SFST), which can be applied in current clinical practice and has already been evaluated in a population of healthy subjects. The purpose of this project is to evaluate the safety, feasibility and validity of SFST in a population of patients with coronary artery disease.

NCT ID: NCT03490903 Not yet recruiting - Clinical trials for Coronary Artery Disease

Coronary Angiography THerapeutic Virtual Reality

CATH-VR
Start date: June 1, 2018
Phase: N/A
Study type: Interventional

The CATH-VR study will investigate the effect of virtual reality (VR) on patient pain, anxiety, and radial artery vasospasm during coronary angiography. Our hypothesis is that the use of VR will decrease patient anxiety and pain via validated scoring systems, as well as show a low rate of vasospasm of the radial artery. In addition, we hypothesize that the amount of opioid and benzodiazepine medications utilized for procedural sedation will be lower in the intervention arm. VR has gained recent attraction as an alternative or adjunctive treatment option for pain, but its effect on reducing procedural sedation has not been studied. We propose a single center, randomized control pilot study to further investigate. The patient population will include adults older than 18 years who present for outpatient diagnostic coronary angiography.

NCT ID: NCT03489863 Not yet recruiting - Clinical trials for Coronary Artery Disease

Prasugrel Versus Ticagrelor in Patients With CYP2C19 Loss-of-function: a Validation Study

Start date: May 2018
Phase: Phase 4
Study type: Interventional

Polymorphisms of the cytochrome P450 (CYP) 2C19 enzyme has been consistently shown to modulate clopidogrel response. Accordingly, the Food and Drug Administration (FDA) has issued a warning on the potential for reduced efficacy of clopidogrel among carriers of loss-of-function alleles (LOF) for CYP2C19 and suggest considering alternative antiplatelet therapies for these individuals. The pharmacodynamic (PD) effects of prasugrel and ticagrelor are not affected by CYP2C19 genetic polymorphisms. However, to date there are no head-to-head PD comparisons between these agents among patients with different CYP2C19 genetic polymorphisms, which is currently under investigation in CAD patients undergoing PCI at UF Health-Jacksonville (UFJ 2014-12, NCT 02065479). In order to rule out play of chance findings, pharmacogenetic investigations require external validation cohorts to support the study findings. Therefore, the present randomized study is designed to serve as an external validation cohort conducted in patients with established CAD not undergoing PCI testing the non-inferiority in platelet reactivity of prasugrel versus ticagrelor among CYP2C19 LOF allele carriers.

NCT ID: NCT03487432 Not yet recruiting - Clinical trials for Calcified Coronary Artery Disease (Grade 3)

A ComparIson of Strategies to PrepAre SeveRely CALCified Coronary Lesions

ISAR-CALC
Start date: April 2018
Phase: N/A
Study type: Interventional

The objective of this prospective, multicenter, randomized, open-label trial is to evaluate the completeness of stent expansion following a strategy of lesion preparation with either a Super High-Pressure NC PTCA Balloon (OPN NC) or a Scoring PTCA Balloon (NSE Alpha) after unsuccessful lesion preparation with conventional NC balloon angioplasty in an angiographically well-defined group of patients with severely calcified coronary lesions (grade 3) undergoing coronary stent implantation (SYNERGY everolimus-eluting stent (EES)).